Point72 Asset Management L.P. Acquires Shares of 136,430 Janux Therapeutics, Inc. (NASDAQ:JANX)

Point72 Asset Management L.P. bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 136,430 shares of the company’s stock, valued at approximately $5,715,000.

Other large investors have also modified their holdings of the company. Capstone Investment Advisors LLC acquired a new position in Janux Therapeutics during the 1st quarter worth approximately $1,969,000. Janus Henderson Group PLC grew its holdings in Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Janux Therapeutics during the 1st quarter worth $739,000. Virtu Financial LLC acquired a new position in Janux Therapeutics in the 1st quarter worth $609,000. Finally, Vanguard Group Inc. boosted its position in Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Activity

In related news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00. Following the sale, the insider now owns 2,959,175 shares of the company’s stock, valued at approximately $139,081,225. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00. Following the sale, the insider now owns 2,959,175 shares of the company’s stock, valued at approximately $139,081,225. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Andrew Hollman Meyer sold 50,000 shares of the stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the transaction, the insider now directly owns 67,592 shares of the company’s stock, valued at approximately $3,106,528.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 393,767 shares of company stock valued at $17,857,979. 35.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

JANX has been the topic of a number of analyst reports. Stifel Nicolaus started coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research note on Monday, August 19th. Wedbush restated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, Scotiabank reduced their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $66.13.

Janux Therapeutics Price Performance

Shares of JANX opened at $44.50 on Wednesday. The stock has a market capitalization of $2.31 billion, a PE ratio of -36.48 and a beta of 3.57. The business’s fifty day moving average price is $43.85 and its 200 day moving average price is $44.68. Janux Therapeutics, Inc. has a 12-month low of $5.65 and a 12-month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.20. The business had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. Janux Therapeutics’s revenue for the quarter was up 709.1% compared to the same quarter last year. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.